Korea Research Institute of Bioscience and Biotechnology

Kiwon Jo

Young Woo Park

Ji Hyun Park

Jong-Ho Park

Jung Jae Yu

Hyo Jeong Hong

Jeong Ho Yoon

Semi Kim

Joon-Goo Jung

So-Young Choi

Young-Soon Jang

Donghee Lee

Yun Jung Park

Young-soon Jang

Eun Jin Kim

Kwang Pyo Lee

So Jeong Park

Heekyung Jung

Chan-Woong Park

A recombinant expression vector, comprising extracellular soluble domain genes of DLK1 and IgG antibody Fc domain genes, is constructed, and DLK1-Fc fusion protein is expressed and purified at 293E cell. The invention confirmed the efficacy as a drug for inhibiting cancer metastasis by confirming markedly reduced migration of cancer cells by DLK1-Fc fusion protein and also computing pharmacokinetic parameters. DLK1-Fc fusion protein has relatively higher stability than non-fusion protein, significantly reduces migration of various cancer cell lines, and provides superior cancer metastasis inhibition effect even at small concentration. Accordingly, DLK1-Fc fusion protein can be used efficaciously as an effective ingredient of a composition for inhibiting cancer metastasis.

Method for inhibiting cancer metastasis by administration of the extracellular domain DLK1 or a DLK1-FC fusion protein

The present invention relates to an anticancer agent containing a TMPRSS4 (transmembrane protease, serine 4) inhibitor as an effective ingredient, more precisely an anticancer agent containing an inhibitor of TMPRSS4 activity as an effective ingredient. The anticancer agent of the present invention can be used effectively for the treatment of cancer by inhibiting TMPRSS4 expression in cancer cells and thereby inhibiting cancer cell invasion and cancer cell growth.

Anticancer drug comprising inhibitor of TMPRSS4

Growing community of inventors

Yongin-si, South Korea

Kiwon Jo